Loading viewer...
investor_presentation
Format: PDF investor_presentation
Annual Shareholders’ Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer
Annual Shareholders’
Dow R. Wilson, President and Chief Executive Officer2Forward -Looking Statements
Except forhistorical information, thispresentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements
concerning industry outlook, including growth drivers, future trends incancer incidence andtrends incancer treatment needs, demand, innovation andgrowth opportunities ;Varian
Medical Systems, Inc.’s(”Varian” orthe“company”) future orders, revenues, backlog orearnings growth ;future financial results ;market acceptance ofortransition tonew products
ortechnology such asourEdge®radiosurgery system, TrueBeam®,HyperArcTM,360OncologyTM,HALCYONTM,image -guided radiation therapy, stereotactic radiosurgery and
proton therapy, andanystatements using theterms “could”, “believe”, “expect”, “outlook”, “anticipate”, ”vision”, “estimate”, “future”, “horizon”, “aiming”, “driving”, “target” orsimilar
statements areforward -looking statements thatinvolve risks anduncertainties thatcould cause thecompany’s actual results todiffer materially from those anticipated .Such risks
anduncertainties include global economic conditions andchanges totrends forcancer treatment regionally ;theimpact ofchanges totheAffordable Health Care forAmerica Act
(including excise taxes onmedical devices) andanyfurther healthcare reforms (including changes toMedicare andMedicaid), and/or changes tothird-party reimbursement levels ;
currency exchange rates andtaxrates ;theimpact oftheTaxCuts andJobs Act;demand forthecompany’s products ;thecompany’s ability todevelop, commercialize, anddeploy
new products ;thecompany’s ability tomeet Food and Drug Administration (FDA) and other regulatory requirements forproduct clearances ortocomply with FDA and other
regulatory regulations orprocedures, changes intheregulatory environment, including withrespect toFDA requirements ;thecompany’s assessment ofthegoodwill associated with
itsparticle therapy business, challenges associated with thesuccessful commercialization ofthecompany’s particle therapy business ;therisks associated with providing financing
fortheconstruction andstart-upoperations ofproton therapy centers ;theeffect ofadverse publicity ;thecompany’s reliance onsole orlimited -source suppliers ;thecompany’s ability
tomaintain orincrease margins ;theimpact ofcompetitive products andpricing ;thepotential loss ofkeydistributors orkeypersonnel ;challenges topublic tender awards andthe
loss ofsuch awards orother orders ;andtheother risks listed from time totime inthecompany’s filings with theSecurities andExchange Commission, which bythisreference are
incorporated herein .The company assumes noobligation toupdate orrevise theforward -looking statements inthispresentation because ofnew information, future events, or
otherwise .Reconciliations toGAAP financials canbefound athttp://investors .varian .com/financialstatements andtheappendix tothispresentation .
Medical Advice Disclaimer
Preview truncated — download the full document for the complete content.
conference
27 Pages
investor_presentation
80 Pages
Rocket Pharmaceuticals